Therapy Areas
Frankel Named to Precision BioSciences B oard of Directors
13 April 2021 - - US-based biotechnology company Precision BioSciences, Inc. (NASDAQ: DTIL) has appointed Stanley R. Frankel, M.D. as a director on the company's board of directors and a member of the board's Science and Technology Committee, the company said.

Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies.

He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.

Dr. Frankel was most recently the senior vice president, Cellular Therapy Development at Bristol-Myers Squibb (NYSE: BMY) where he was responsible for late development portfolio of cellular therapy assets including Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).

While at BMS, he sat on multiple leadership teams and committees, including the Global Drug Development Leadership Team and the Cell Therapy Commercial Steering Committee.

Prior to the BMS acquisition of Celgene, he was Corporate vice president, Head, Immuno-Oncology and Cellular Therapy, Clinical Research and Development Head, Cell Therapy Clinical Center of Excellence at Celgene.

While at Celgene he co-chaired the Hematology-Oncology Development Committee and served on the Hematology-Oncology Franchise Leadership Team. He served on Joint Steering and/or Joint Development Committees for alliances with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.

Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986.

He completed his residency in internal medicine at Mount Sinai Hospital and his fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center where he was Chief Fellow.

He has prior academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland prior to joining Columbia University Vagelos College of Physicians and Surgeons as Adjunct Associate Professor of Medicine in the Division of Hematology/Oncology.

Additionally, Tony Yao M.D., Ph.D, a member of Precision's board of directors will continue to serve until his term concludes at the upcoming 2021 stockholders meeting on May 10, 2021.

Dr. Yao has served on Precision's Board, including its Nominating and Corporate Governance Committee, since April 2018. Dr. Yao also chaired the S and T Committee since it was formed in 2020.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS genome editing platform.

ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Using ARCUS, the company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.


Related Headlines